Back To: Home : Featured Technology : Reagents/Proteins

CLICK HERE FOR WHAT'S NEW IN:
 
 
 

PolyTherics, Alligator announce collaboration
July 2008
SHARING OPTIONS:

LONDON—PolyTherics Ltd., a biopharmaceutical company specializing in the targeted application of polymers to bio-pharmaceuticals, and Alligator Bioscience AB, a biotechnology company applying proprietary technology to the improvement of proteins, today announced the establishment of a new alliance.

Under the terms of the collaboration agreement, PolyTherics and Alligator will explore the biological effects of the polymer-based technologies developed by PolyTherics on proteins optimized and provided by Alligator, which is based in Lund, Sweden. The parties intend to use the intellectual property generated by their collaboration to explore the development and commercialization potential of next generation protein-based products.

"A key element of PolyTherics' business strategy is to exploit our proprietary technologies in expanding the product potential of proteins," says Dr. Keith Powell, CEO of PolyTherics. "We have developed and continue to develop technologies to improve every type of protein therapeutic; from antibody fragments to enzymes, both natural and improved. We are excited by the prospects for this collaboration with Alligator and our shared vision of exploring next generation biopharmaceuticals."

Dr. Gun-Britt Fransson, CEO of Alligator, says: "The collaboration with PolyTherics supports Alligator's strategy to further expand its pipeline with optimized drug candidates into new areas of indications. We are excited to see the outcome of combining the two companies' technologies." DDN

Back


PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.